Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: April 1, 2022
Dysregulated
innate
and
adaptive
immunity
is
a
sign
of
SARS-CoV-2-induced
disease
cancer.
CD8
+
T
cells
are
important
the
immune
system.
The
belong
to
take
front-line
defense
against
viral
infections
Extreme
T-cell
activities
in
lung
patients
with
within
tumor
microenvironment
(TME)
will
change
their
functionality
into
exhausted
state
undergo
apoptosis.
Such
diminished
put
cancer
cases
at
high-risk
group
for
disease,
rendering
sepsis
more
severe
condition
which
finally
cause
higher
rate
mortality.
Recovering
responses
from
purpose
vaccination
SARS-CoV-2.
aim
this
review
discuss
cellular
present
some
strategies
recovering
these
critical
cells.
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
164, P. 114954 - 114954
Published: May 29, 2023
Traditionally,
vaccines
have
helped
eradication
of
several
infectious
diseases
and
also
saved
millions
lives
in
the
human
history.
Those
prophylactic
acted
through
inducing
immune
responses
against
a
live
attenuated,
killed
organism
or
antigenic
subunits
to
protect
recipient
real
infection
caused
by
pathogenic
microorganism.
Nevertheless,
development
anticancer
as
valuable
targets
health
has
faced
challenges
requires
further
optimizations.
Dendritic
cells
(DCs)
are
most
potent
antigen
presenting
(APCs)
that
play
essential
roles
tumor
immunotherapies
induction
CD8+
T
cell
immunity.
Accordingly,
various
strategies
been
tested
employ
DCs
therapeutic
for
exploiting
their
activity
cells.
Application
whole
purified/recombinant
peptides
common
approaches
pulsing
DCs,
which
then
injected
back
into
patients.
Although
some
hopeful
results
reported
number
DC
animal
clinical
trials
cancer
patients,
such
still
inefficient
require
optimization.
Failure
vaccination
is
postulated
due
immunosuppressive
microenvironment
(TME),
overexpression
checkpoint
proteins,
suboptimal
avidity
tumor-associated
(TAA)-specific
lymphocytes,
lack
appropriate
adjuvants.
In
this
review,
we
an
overview
current
experiments
evaluated
efficacy
well
focusing
on
improve
potential
including
combination
therapy
with
inhibitors
(ICIs).
Journal of Biochemical and Molecular Toxicology,
Journal Year:
2021,
Volume and Issue:
35(11)
Published: Aug. 31, 2021
Abstract
Solid
cancers
comprise
a
large
number
of
new
cases
and
deaths
from
cancer
each
year
globally.
There
are
strategies
for
addressing
tumors
raised
solid
organs
including
surgery,
chemotherapy,
radiotherapy,
targeted
therapy,
immunotherapy,
combinational
stem
cell
extracellular
vesicle
(EV)
therapy.
Surgery,
chemotherapy
the
dominant
cures,
but
not
always
effective,
in
which
even
localized
tumor
there
is
possibility
relapse
after
surgical
resection.
Over
half
patients
will
receive
radiotherapy
as
part
their
therapeutic
schedule.
Radiotherapy
can
cause
an
abscopal
response
boosting
activity
immune
system
outside
local
field
radiation,
it
may
also
unwanted
bystander
effect,
predisposing
nonradiated
cells
into
carcinogenesis.
In
context
checkpoint
inhibition
known
standard‐of‐care,
major
concern
regard
with
cold
that
show
low
responses
to
such
Stem‐cell
therapy
be
used
send
prodrugs
toward
area;
this
strategy,
however,
has
its
own
predicaments,
attraction
other
sites
healthy
tissues
instability.
A
substitute
quite
novel
strategy
use
EVs,
by
virtue
stability
potential
cross
biological
barriers
long‐term
storage
contents.
Combination
current
focus.
Despite
advances
field,
still
unmet
concerns
area
effective
raising
challenges
opportunities
future
investigations.
Frontiers in Oncology,
Journal Year:
2021,
Volume and Issue:
11
Published: Aug. 12, 2021
Preclinical
and
clinical
antiangiogenic
approaches,
with
multiple
side
effects
such
as
resistance,
have
not
been
proved
to
be
very
successful
in
treating
tumor
blood
vessels
which
are
important
targets
for
therapy.
Meanwhile,
restoring
aberrant
vessels,
known
vascular
normalization,
has
shown
only
capable
of
reducing
invasion
metastasis
but
also
enhancing
the
effectiveness
chemotherapy,
radiation
therapy,
immunotherapy.
In
addition
introduction
methods
promoting
normalization
maintaining
balance
between
proangiogenic
factors
targeting
endothelial
cell
metabolism,
microRNAs,
extracellular
matrix,
latest
molecular
mechanisms
potential
connections
them
were
primarily
explored.
particular,
immunotherapy-induced
further
promotes
infiltration
immune
effector
cells,
turn
improves
immunotherapy,
thus
forming
an
enhanced
loop.
Thus,
immunotherapy
combination
agents
is
recommended.
Finally,
we
introduce
imaging
technologies
serum
markers,
can
used
determine
window
normalization.
Biomedicine & Pharmacotherapy,
Journal Year:
2021,
Volume and Issue:
145, P. 112419 - 112419
Published: Nov. 12, 2021
Interleukin-6
(IL-6)
is
a
multi-tasking
cytokine
that
represents
high
activity
in
patients
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
and
cancer.
High
concentration
of
this
pleiotropic
accounts
for
hyperinflammation
storm,
related
to
multi-organ
failure
SARS-CoV-2
induced
disease.
IL-6
promotes
lymphopenia
increases
C-reactive
protein
(CRP)
such
cases.
However,
blockade
not
full-proof
complete
response.
Hypoxia,
hypoxemia,
aberrant
angiogenesis
chronic
inflammation
are
inter-related
events
occurring
as
response
the
stimulatory
effect
on
activity.
Taking
both
pro-
anti-inflammatory
activities
will
make
complex
targeting
patient
The
aim
review
was
discuss
about
interactions
within
body
disease
who
representing
levels,
determine
whether
inhibition
therapy
effective
or
not.
We
also
address
targeted
therapies
cancer
have
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: June 29, 2022
Atherosclerosis
is
one
of
the
main
complications
diabetes
mellitus,
involving
a
variety
pathogenic
factors.
Endothelial
dysfunction,
inflammation,
and
oxidative
stress
are
hallmarks
mellitus
atherosclerosis.
Although
ability
to
promote
atherosclerosis
has
been
demonstrated,
deeper
understanding
underlying
biological
mechanisms
critical
identifying
new
targets.
NLRP3
plays
an
important
role
in
both
While
diversity
its
activation
modes
causes
complex
effects
progression
atherosclerosis,
it
also
provides
many
insights
for
targeted
interventions
metabolic
diseases.
Cancer Medicine,
Journal Year:
2022,
Volume and Issue:
11(15), P. 2934 - 2943
Published: March 17, 2022
Immunotherapy
using
immune
checkpoint
inhibitors
(ICIs)
is
the
current
focus
in
cancer
immunotherapy.
However,
issues
are
raised
area,
as
recent
studies
showed
that
such
therapeutic
modality
suffers
from
low
durability
and
or
no
efficacy
for
patients
with
some
tumor
types
including
cases
non-inflamed
cold
cancers.
Therefore,
efforts
have
been
made
to
solve
issue
combination
therapy,
use
of
immunocytokines.
The
ICI
interleukins
(ILs)
IL-targeting
agents
now
under
consideration
area
primary
results
promising.
this
review
discuss
possibility
ILs
drugs
immunotherapy
describing
advances
field
PEGylated
fusion
proteins.
key
reduce
adverse
events
increase
therapy.
